These findings imply that specifically targeting Smad3 may be a good therapeutic strategy for treatment of T2D and T2DN, which was examined in the present study by treating diabetic db/db mice with a Smad3-specific inhibitor SIS3. This evidence concerns the gene SMAD3 and type 2 diabetes mellitus.